Patents Governing KP415 and KP484 The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA. View real-time stock prices and stock quotes for a full financial overview. (KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Patents Governing KP415 and KP484KemPharm Announces Issuance of Two Additional U.S. Following this transaction Laduane Clifton’s holding ...[...]KemPharm Reports Second Quarter 2020 Financial ResultsDelisting of Securities of KemPharm, Inc.; Endologix, Inc.; VIVUS, Inc.; SAExploration Holdings, Inc.; Ascena Retail Group, Inc.; and Global Eagle Entertainment Inc. from The Nasdaq Stock MarketDelisting of Securities of KemPharm, Inc.; Endologix, Inc.; VIVUS, Inc.; SAExploration Holdings, Inc.; Ascena Retail Group, Inc.; and Global Eagle Entertainment Inc. from The Nasdaq Stock MarketKemPharm to Report Second Quarter 2020 Financial ResultsKemPharm to Report Second Quarter 2020 Financial ResultsKemPharm Announces Issuance of Two Additional U.S.

Asian markets muted as traders warily await U.S. stimulus deal By using our website or by closing this message box, you agree to our use of browser capability checks, and to our use of cookies as described in our KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs.

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central... Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Get the latest KEMPHARM INC (KMPH) stock news and headlines to help you in your trading and investing decisions. We use cookies and browser capability checks to help us deliver our online services, including to learn if you enabled Flash for video or ad blocking.

Market Activity ... BUZZ-U.S. STOCKS ON THE MOVE … China's economic activity improves in July Copyright © 2020 MarketWatch, Inc. All rights reserved. View the latest KemPharm Inc. (KMPH) stock price, news, historical charts, analyst ratings and financial information from WSJ. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.

Find the latest news headlines from KemPharm Inc. (KMPH) at Nasdaq.com. Log in to see them here or sign up to get started.Create a list of the investments you want to track.Visit a quote page and your recently viewed tickers will be displayed here.KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2020 Results - Earnings Call TranscriptKemPharm issued new U.S. patents for SDX-based product candidatesYesterday, the CFO, Secretary & Treasurer of KemPharm (KMPH), Laduane Clifton, bought shares of KMPH for $285. By using this site you agree to the The stock market hasn’t seen a 100-day gain this strong since 1933

KMPH | Complete KemPharm Inc. stock news by MarketWatch. Data may be intentionally delayed pursuant to supplier requirements. What is KemPharm's stock symbol? Have Watchlists? Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers. ]Today, the CFO, Secretary & Treasurer of KemPharm (KMPH), Laduane Clifton, bought shares of KMPH for $2,070. Skip to main content.